• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

2.860 -2.510 (-46.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
Myriad Genetics Q2 Earnings Call Highlights ↗
Today 21:02 EDT
Myriad Genetics (NASDAQ:MYGN) reported second-quarter 2026 revenue of $190.7 million, down 11% from a year earlier, as a 1% decline in total test volume and a 9% decrease in revenue per test weighed on... 
Via MarketBeat
Topics Artificial Intelligence Earnings
Top movers in Friday's session ↗
Today 15:00 EDT
Via Chartmill
News headline image
Why Myriad Genetics (MYGN) Shares Are Falling Today
Today 14:30 EDT
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 46.1% in the afternoon session after the company reported disappointing s... 
Via StockStory
Topics Artificial Intelligence
Top stock movements in today's session. ↗
Today 12:30 EDT
Via Chartmill
Myriad Genetics (NASDAQ:MYGN) Plunges 26% After Fiscal Q2 Revenue and EPS Miss, Slashes Full-Year Guidance ↗
July 30, 2026
Via Chartmill
Gapping stocks in Friday's session ↗
Today 10:30 EDT
Via Chartmill
Friday's pre-market session: top gainers and losers ↗
Today 8:30 EDT
Via Chartmill
Thursday's after hours session: top gainers and losers ↗
July 30, 2026
Via Chartmill
News headline image
Myriad Genetics (NASDAQ:MYGN) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 28.6%
July 30, 2026
Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 10.5% year on year to ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
July 30, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics (MYGN) Reports Q2: Everything You Need To Know Ahead Of Earnings
July 28, 2026
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting earnings this Thursday after market hours. Here’s what you need to know. Myriad Genet... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Unprofitable Stocks That Fall Short
July 27, 2026
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv... 
Via StockStory
News headline image
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
July 23, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
3 Reasons MYGN is Risky and 1 Stock to Buy Instead
July 23, 2026
Myriad Genetics has been treading water for the past six months, recording a small loss of 3.6% while holding steady at $5.66. The stock also fell short of t... 
Via StockStory
News headline image
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen
July 21, 2026
The only lab test to run four prenatal genetic screens simultaneously as early as eight weeks gestation 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
July 02, 2026
Findings from 14 studies involving more than 8,000 patients show Prolaris adds insight beyond conventional clinical risk categories 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
1 Unpopular Stock That Should Get More Attention and 2 We Find Risky
July 01, 2026
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
News headline image
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
June 29, 2026
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers. Over th... 
Via StockStory
Topics Artificial Intelligence
News headline image
Why Is Myriad Genetics (MYGN) Stock Rocketing Higher Today
June 24, 2026
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 9.2% in the morning session after the company expanded the availability... 
Via StockStory
News headline image
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
June 23, 2026
Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
1 Cash-Burning Stock with Promising Prospects and 2 Facing Headwinds
June 05, 2026
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses... 
Via StockStory
Topics Bankruptcy
News headline image
3 High-Flying Stocks We’re Skeptical Of
June 04, 2026
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo... 
Via StockStory
News headline image
Myriad Genetics Names Raj Jampa as New Chief Technology Officer
June 02, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
May 27, 2026
Six ASCO abstracts and an industry expert theater session underscore Myriad’s leadership in the cancer care continuum 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
May 26, 2026
New PATHOMIQ AI integration helps clinicians tailor active surveillance with greater confidence 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
1 Unprofitable Stock to Consider Right Now and 2 We Turn Down
May 22, 2026
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
Topics Energy
News headline image
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
May 15, 2026
The Netflix star partners with Myriad Genetics to tell her BRCA1 story and why she wants everyone to know about hereditary cancer testing 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions
May 12, 2026
Myriad Genetics began 2026 with results that fell short of Wall Street’s expectations, as the company posted modest year-over-year sales growth but missed on... 
Via StockStory
Topics Earnings
News headline image
3 of Wall Street’s Favorite Stocks with Open Questions
May 12, 2026
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
May 07, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap